Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KYMR 
Kymera Therapeutics Inc (KYMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KYMR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $61
1 Year Target Price $61
| 14 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 89.69% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.06B USD | Price to earnings Ratio - | 1Y Target Price 61 |
Price to earnings Ratio - | 1Y Target Price 61 | ||
Volume (30-day avg) 20 | Beta 2.07 | 52 Weeks Range 19.45 - 53.27 | Updated Date 07/1/2025 |
52 Weeks Range 19.45 - 53.27 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.11 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -336.77% |
Management Effectiveness
Return on Assets (TTM) -19.47% | Return on Equity (TTM) -32.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2680930083 | Price to Sales(TTM) 52 |
Enterprise Value 2680930083 | Price to Sales(TTM) 52 | ||
Enterprise Value to Revenue 45.53 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 70164096 | Shares Floating 41673919 |
Shares Outstanding 70164096 | Shares Floating 41673919 | ||
Percent Insiders 2.69 | Percent Institutions 111.66 |
Analyst Ratings
Rating 4 | Target Price 61 | Buy 3 | Strong Buy 14 |
Buy 3 | Strong Buy 14 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kymera Therapeutics Inc
Company Overview
History and Background
Kymera Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins, pioneering targeted protein degradation (TPD).
Core Business Areas
- Targeted Protein Degradation: Kymera's core business is the development of protein degraders that target specific proteins involved in disease pathways. They design heterobifunctional molecules that recruit E3 ligases to tag target proteins for degradation.
- Drug Discovery and Development: Kymera engages in drug discovery, preclinical research, and clinical development, moving potential therapies from the laboratory to human trials.
- Partnerships and Licensing: Kymera collaborates with other pharmaceutical companies to develop and commercialize its TPD technology, generating revenue through licensing agreements and milestone payments.
Leadership and Structure
Nello Mainolfi, PhD, is the President and CEO. The company has a board of directors and a management team overseeing research, development, finance, and operations.
Top Products and Market Share
Key Offerings
- KT-474 (SAR444229): A IRAK4 degrader being developed in collaboration with Sanofi. It is in clinical trials for hidradenitis suppurativa, atopic dermatitis and other inflammatory conditions. Market share data is not yet applicable as the product is still in clinical development. Competitors: Biogen, Janssen, Novartis.
- KT-333: A STAT3 degrader in clinical trials for relapsed/refractory lymphomas and solid tumors. Market share data is not yet applicable as the product is still in clinical development. Competitors: Relay Therapeutics, Voronoi.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and focuses on developing new therapies for various diseases. Targeted protein degradation represents an emerging modality.
Positioning
Kymera is a leader in the TPD field, holding a strong intellectual property portfolio and advanced clinical programs. They have a first-mover advantage but face increasing competition.
Total Addressable Market (TAM)
The TAM for protein degradation therapies is potentially very large, estimated in the tens of billions of dollars, as it offers a novel approach to target previously undruggable proteins. Kymera is positioned to capture a significant portion of this market if their clinical programs are successful.
Upturn SWOT Analysis
Strengths
- Pioneering TPD technology
- Strong intellectual property
- Experienced leadership team
- Strategic partnerships (Sanofi, Vertex)
- Advanced clinical programs
Weaknesses
- High R&D costs
- Clinical trial risks
- Dependence on partnerships
- Relatively small company size
- Limited revenue stream
Opportunities
- Expansion into new therapeutic areas
- Development of new protein degraders
- Increased adoption of TPD technology
- Potential for breakthrough therapies
- Partnerships with big pharma
Threats
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturns
- Patent challenges
Competitors and Market Share
Key Competitors
- VRTX
- MRTX
- ARVN
Competitive Landscape
Kymera faces competition from established pharmaceutical companies and other emerging biotechnology companies developing TPD therapies or similar modalities. Their competitive advantage lies in their first-mover advantage, proprietary technology, and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Kymera's historical growth is characterized by rapid expansion of its research pipeline and increasing partnerships.
Future Projections: Future growth is projected to be driven by successful clinical trial outcomes and regulatory approvals of its lead drug candidates. Analyst estimates vary widely depending on the success of its clinical programs.
Recent Initiatives: Recent initiatives include the advancement of KT-474 and KT-333 into later-stage clinical trials, expanding research into new disease areas, and strengthening partnerships.
Summary
Kymera Therapeutics is a promising company in the emerging field of targeted protein degradation. The company has strong partnerships and a robust pipeline, but faces significant clinical and regulatory risks. Financial stability is heavily reliant on successful clinical trials and continued investment. It is important to watch the clinical trial results to understand how the company is performing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kymera Therapeutics Inc. Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 208 | Website https://www.kymeratx.com |
Full time employees 208 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.